P/B
8,2
Novartis
Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
$304.6B
Market Cap • 11/12/2026
1996
(30 years)
Founded
1996
(30 years ago)
IPO
NYSE
Listing Exchange
Switzerland
Country
Valuation
P/S
5,3
P/EBITDA
16,4
P/OCF
17,6
P/FCF
19,5
P/E
30,6
BVPS
19,6
EPS
5,2
Market Cap
Market Cap
304,6B
EV
344,3B
EV/Revenue
6
EV/EBITDA
18,5
EV/EBIT
23,8
Payout
Dividend Per Share
4,8
Dividend Yield
3%
Buyback Yield
2%
Total Yield
5%
Dividend Yield 5Y
3,3%
Payout
90,5%
Retained Earnings
36,5B
Profitability
Gross Margin
74,9%
EBITDA Margin
32,4%
EBIT Margin
25,2%
Net Margin
17,5%
D&A/EBITDA
0%
R&D/Revenue
24,2%
Capex/Revenue
2,9%
Capex/D&A
40,2%
Capex/OCF
9,6%
SBC/OCF
5%
% PPE
10,5%
% Goodwill
23,2%
ROE
24,3%
ROIC
12,4%
Growth
CAGR Revenue 5Y
1,8%
CAGR Op. Income 5Y
4,2%
CAGR Net Income 5Y
0,4%
CAGR EPS 5Y
3,9%
CAGR OCF 5Y
2,7%
Leverage
N.D./EBITDA
2,1
Debt/Equity
0%
Current Ratio
0,9
Quick Ratio
0,6
Interest Coverage
915,9%
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!